Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, specializing in the development of innovative therapies for central nervous system (CNS) disorders. The company is advancing a promising pipeline that addresses unmet medical needs in pain management and psychiatric conditions, utilizing cutting-edge research and technology. With a strong commitment to improving patient outcomes and tackling significant healthcare challenges, Relmada is positioned to be a key player in the dynamic CNS therapeutics market, potentially offering transformative solutions that enhance patient care and quality of life. Show more

Location: 2222 PONCE DE LEON BLVD., CORAL GABLES, FL, UNITED STATES, 33134, Coral Gables, FL, 33134, USA | Website: https://www.relmada.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

330.7M

52 Wk Range

$0.24 - $5.12

Previous Close

$3.60

Open

$3.61

Volume

478,812

Day Range

$3.60 - $3.95

Enterprise Value

253.8M

Cash

1.384M

Avg Qtr Burn

-6.722M

Insider Ownership

10.75%

Institutional Own.

19.74%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NDV-01 Details Non-muscle invasive bladder cancer (NMIBC)	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sepranolone Details Prader Willi syndrome	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sepranolone Details Tourette syndrome	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REL-P11 (psilocybin) Details Obesity, Metabolic disorder	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
REL-1017 Details Major depressive disorder, Mental health	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.